ClinicalTrials.gg

Program

apazunersen sodium

Also written as “GTX-102”, “GTX-102 medium dose fast Period 1 and Period 2” and “GTX-102 medium dose slow Period 1 and Period 2”.

Its studies are mostly in Angelman Syndrome · Ataxia Telangiectasia, led by 2 companies.

Furthest: phase 3, since May 10, 20245 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ultragenyx Pharmaceutical40 open or runningphase 3since May 10, 2024Jan 31, 2020none ahead
Grace Therapeutics10 open or runningphase 1since Aug 31, 2022Aug 31, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2020First study: phase 2 study in Angelman SyndromeNew to Ultragenyx PharmaceuticalUltragenyx Pharmaceutical · NCT04259281 · 74 enrolled · United States, Australia, Canada and more
  2. Aug 31, 2022Grace Therapeutics's first study: phase 1 study in Ataxia TelangiectasiaNew to Grace TherapeuticsGrace Therapeutics · NCT05531890 · 48 enrolled · Canada
  3. May 10, 2024Phase 3 study in Angelman SyndromeUltragenyx Pharmaceutical · NCT06415344 · 66 enrolled · United States, Australia, Canada and more
  4. Sep 24, 2024Phase 3 study in Angelman SyndromeUltragenyx Pharmaceutical · NCT06617429 · 129 enrolled · United States, Canada, Germany and more
  5. Aug 21, 2025Phase 2 study in Angelman SyndromeUltragenyx Pharmaceutical · NCT07157254 · 55 enrolled · United States, Argentina, Brazil and more
  6. Nov 3, 2026Phase 3 study terminatedStudy stoppedNCT06415344 · “Lack of efficacy”
  7. Nov 3, 2026Phase 3 study terminatedStudy stoppedNCT06617429 · “Lack of efficacy”
  8. Nov 3, 2026Phase 2 study terminatedStudy stoppedNCT07157254 · “Lack of efficacy”

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07157254Angelman Syndrome · United States, Argentina, Brazil and more2TerminatedUltragenyx PharmaceuticalOct 30, 202655
NCT06617429Angelman Syndrome · United States, Canada, Germany and more3TerminatedUltragenyx PharmaceuticalJul 10, 2026129
NCT06415344Angelman Syndrome · United States, Australia, Canada and more3TerminatedUltragenyx PharmaceuticalOct 30, 202666
NCT05531890Ataxia Telangiectasia · Canada1UNKNOWNGrace TherapeuticsNov 24, 202248
NCT04259281Angelman Syndrome · United States, Australia, Canada and more2CompletedUltragenyx PharmaceuticalJan 8, 202574

How it is read

Names in the registry

  • “GTX-102”, 4 entries
  • “GTX-102 medium dose fast Period 1 and Period 2”, 1 entry
  • “GTX-102 medium dose slow Period 1 and Period 2”, 1 entry
  • “GTX-102 high dose fast Period 1 and Period 2”, 1 entry
  • “GTX-102 low dose fast Period 1 and Period 2”, 1 entry

Codes read as this program: GTX102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.